Coherus Biosciences (NASDAQ:CHRS) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.
Valuation and Earnings
This table compares Coherus Biosciences and Vericel’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coherus Biosciences||$1.56 million||436.92||-$238.17 million||($4.48)||-2.24|
|Vericel||$63.92 million||10.77||-$17.28 million||($0.50)||-32.22|
Vericel has higher revenue and earnings than Coherus Biosciences. Vericel is trading at a lower price-to-earnings ratio than Coherus Biosciences, indicating that it is currently the more affordable of the two stocks.
This table compares Coherus Biosciences and Vericel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Coherus Biosciences has a beta of 3.72, meaning that its share price is 272% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.36, meaning that its share price is 236% more volatile than the S&P 500.
Insider and Institutional Ownership
91.3% of Coherus Biosciences shares are held by institutional investors. Comparatively, 76.6% of Vericel shares are held by institutional investors. 26.3% of Coherus Biosciences shares are held by company insiders. Comparatively, 3.3% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current ratings for Coherus Biosciences and Vericel, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Coherus Biosciences presently has a consensus price target of $30.75, indicating a potential upside of 205.97%. Vericel has a consensus price target of $16.75, indicating a potential upside of 3.97%. Given Coherus Biosciences’ higher possible upside, equities research analysts clearly believe Coherus Biosciences is more favorable than Vericel.
Coherus Biosciences beats Vericel on 7 of the 13 factors compared between the two stocks.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.